Last updated: 11/07/2018 11:01:40
Study to determine the bioequivalence of two fixed dose combination (FDC) tablet formulations of amlodipine and losartan FDC5/50 and FDC5/100 under fasting conditions
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: An open-label, randomised, single dose, three-way crossover, parallel groups study to determine the bioequivalence of two fixed dose combination (FDC) tablet formulations of amlodipine and losartan FDC5/50 and FDC5/100 to respective reference dosages in healthy adult male and female subjects under fasting conditions
Trial description: This is a three-period, three sequence, reference replicated, cross-over study to determine the bioequivalence of two amlodipine and losartan FDC tablet formulations FDC5/50 and FDC5/100 (GSK2944406; 5 mg amlodipine and 50 mg and 100 mg losartan) to reference amlodipine and losartan tablets co-administered in two groups enrolling 102 healthy adult male and female subjects under fasting conditions.A description of each treatment is provided below:A (Reference) = 1 x 5 mg amlodipine tablet and 1 x 50 mg losartan tablet.B (FDC5/50) = 1 x 5 mg amlodipine and 50 mg losartan tablet C (Reference) = 1 x 5 mg amlodipine tablet and 1 x 100 mg losartan tablet D (FDC5/100) = 1 x 5 mg amlodipine and100 mg losartan tablet The treatments will be administered in accordance with the randomisation schedule as.Group 1: A → A → B or A → B → A or B → A → AGroup 2: C → C → D or C → D → C or D → C → CAll subjects will attend a screening visit within 28 days of their first dosing period (Day 1). The baseline assessments will be conducted the day before the first dosing.In each treatment period, subjects will be admitted to the clinic in the evening before Day 1. All subjects will receive a single oral dose of amlodipine and losartan in the morning on Day 1. All the subjects will remain in the clinical unit until completion of all assessments at 24 hours post-dose on Day 2 including collection of the 24 hour post-dose PK sample. Subjects will return to the clinic for pharmacokinetic samples at 36, 48, 72 and 96 hours post-dose.The three treatment periods will be separated by a washout period of 10-17 days. Upon completion of the last dosing period, or early withdrawal, subjects will return to the clinical unit within 14-21 days for a follow up visit.
Primary purpose:
Treatment
Trial design:
Crossover Assignment
Masking:
None (Open Label)
Allocation:
Randomized
Primary outcomes:
Plasma pharmacokinetic parameters for amlodipine and losartan in relevant treatments
Timeframe: Up to 25 days at regular time points
Secondary outcomes:
Plasma pharmacokinetic (PK) parameters tmax, Clast, percentage AUCex and t½ for amlodipine and losartan
Timeframe: Up to 25 Days at regular time points
Plasma Pharmacokinetic parameters for carboxylic acid (active losartan metabolite)
Timeframe: Up to 25 Days at regular time points
Measure of clinical laboratory test values to access safety and tolerability
Timeframe: Up to 45 Days
Safety assessed by vital sign measurements
Timeframe: Up to 45 Days
Number of subjects with adverse events (AE)s
Timeframe: Up to 45 Days
Interventions:
Drug: Reference Treatment: 5 mg amlodipine + 50 mg losartan
Drug: Reference Treatment:5 mg amlodipine + 100 mg losartan
Drug: FDC 5/50 amlodipine/ losartan
Drug: FDC 5/100 amlodipine /losartan
Enrollment:
102
Observational study model:
Not applicable
Primary completion date:
Not applicable
Time perspective:
Not applicable
Clinical publications:
S Chung, J Bianco, J Bullman, A Stylianou, K Patterson. Evaluation of Bioequivalence of a Fixed Dose Combination of Amlodipine and Losartan: Results from Two Phase I Clinical Trials. British Pharmacological Society - Pharmacology 2014. 2014;12(3)
Medical condition
Hypertension
Product
amlodipine, amlodipine/losartan, losartan
Collaborators
No
Study date(s)
May 2013 to July 2013
Type
Interventional
Phase
1
Participation criteria
Sex
Female & Male
Age
18 - 65 years
Accepts healthy volunteers
Yes
- Age & Gender: Male or female between 18 and 65 years of age inclusive, at the time of signing the informed consent.
- Body weight >= 50 kg and body mass index (BMI) within the range 18.5 to 24.9 kilogram/meter squared.
- The subject has a positive: drug/alcohol screen, Hepatitis, human immunodeficiency virus(HIV) screen
- Subject with systolic blood pressure less than 90 mmHg or diastolic less than 60 mm Hg irrespective of associated symptoms at the time of admission
Inclusion and exclusion criteria
Inclusion criteria:
- Age & Gender: Male or female between 18 and 65 years of age inclusive, at the time of signing the informed consent.
- Body weight >= 50 kg and body mass index (BMI) within the range 18.5 to 24.9 kilogram/meter squared.
- Alanine aminotransferase (ALT) alkaline phosphatase and bilirubin
- Normal electrocardiogram (ECG) measurements. Average QT duration corrected for heart rate by Fridericia’s formula (QTcF) <450 millisecond (msec) or QTcF <480 msec in subjects with Bundle Branch Block based on an average from three ECGs obtained over a brief recording period.
- Female subjects of non-child bearing potential. Females of child bearing potential are eligible to enter if they are not pregnant and willing to use protocol-specified methods of contraception to prevent pregnancy.
- Healthy as determined by a responsible and experienced physician, based on a medical Evaluation.
- Capable of giving written informed consent.
Exclusion criteria:
- The subject has a positive: drug/alcohol screen, Hepatitis, human immunodeficiency virus(HIV) screen
- Subject with systolic blood pressure less than 90 mmHg or diastolic less than 60 mm Hg irrespective of associated symptoms at the time of admission
- If there is a drop in 20 mmHg of systolic pressure (and a 10 mmHg drop in diastolic) and a 20 beats per minute increase in heart rate between supine measurement and after two minutes standing at the time of admission.
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- A positive pre-study drug/alcohol at the time of admission.
- Abuse of alcohol
- Participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer)
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John’s Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GlaxoSmithKline (GSK) Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
- Donation of more than 500 milliliter (mL) blood within a 56 day period.
- Pregnant or lactating females.
- Unwillingness or inability to follow the procedures outlined in the protocol.
- Subject is mentally or legally incapacitated.
- History of sensitivity to heparin or heparin-induced thrombocytopenia.
- Subject having positive urinary cotinine levels indicative of use of tobacco or nicotine-containing products within 6 months prior to screening.
- Subjects who have asthma or a history of asthma including childhood asthma.
- Unable to refrain from consumption of red wine, Seville oranges, grapefruit or grapefruit juice from 7 days prior to the first dose.
Trial location(s)
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
Protocol
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Completed
Actual primary completion date
Not applicable
Actual study completion date
2013-25-07
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereResults for study 116799 can be found on the GSK Clinical Study Register.
Click hereAccess to clinical trial data by researchers
Visit website